| Name | Title | Contact Details |
|---|
Benefit & Risk Management Services is a Folsom, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Community Hospital Corporation owns, manages and consults with hospitals through three distinct organizations — CHC Hospitals, CHC Consulting and CHC ContinueCARE, which share a common purpose to guide, support and enhance the mission of community hospitals and healthcare providers.
QR Systems Inc is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Founded in 1995, California Healthcare Medical Billing offers advanced technology and business services to optimize healthcare performance and profitability, delivering a wide range of IT and revenue cycle management solutions to physician practices, IPAs, MSOs, hospitals and health systems nationwide. Highly regarded for exceptional customer service, CHMB’s proficiency has helped thousands of clients maximize reimbursements, reduce costs and increase cash flow. Building upon this expertise, California Healthcare Medical Billing provides automated clinical and administrative solutions to improve patient care and administrative efficiency, including application hosting, implementation, training and support of leading electronic health record (EHR) and practice management (PM) systems.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.